China Cord Blood Corporation (NYSE:CO) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $10.70 and last traded at $10.66, with a volume of 423,060 shares traded. The stock had previously closed at $10.28.
Separately, BidaskClub upgraded China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a report on Tuesday.
The stock has a 50 day moving average price of $9.93 and a 200 day moving average price of $7.58. The stock has a market capitalization of $1.45 billion, a P/E ratio of 51.11 and a beta of 0.94.
China Cord Blood Corporation (NYSE:CO) last released its earnings results on Wednesday, June 21st. The medical research company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.02. China Cord Blood Corporation had a net margin of 16.46% and a return on equity of 7.05%. The firm had revenue of $29.35 million during the quarter. On average, equities analysts expect that China Cord Blood Corporation will post $0.15 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parametrica Management Ltd bought a new position in China Cord Blood Corporation during the second quarter worth $149,000. Spark Investment Management LLC acquired a new position in China Cord Blood Corporation during the first quarter valued at approximately $204,000. Brandes Investment Partners LP acquired a new position in China Cord Blood Corporation during the first quarter valued at approximately $263,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in China Cord Blood Corporation by 12.2% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 40,870 shares of the medical research company’s stock valued at $272,000 after buying an additional 4,442 shares during the period. Finally, Financial Counselors Inc. increased its position in China Cord Blood Corporation by 6.0% in the first quarter. Financial Counselors Inc. now owns 92,056 shares of the medical research company’s stock valued at $613,000 after buying an additional 5,226 shares during the period. 18.30% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “China Cord Blood Corporation (CO) Sets New 1-Year High at $10.70” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/05/china-cord-blood-corporation-co-reaches-new-1-year-high-at-10-70-updated.html.
China Cord Blood Corporation Company Profile
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
